THE GOAL OF THIS PHASE I RESEARCH IS TO DEVELOP A NOVEL NONAGGLUTINATION METHOD FOR PRECISE, RAPID, AND COST- EFFECTIVE IDENTIFICATION OF CLINICALLY SIGNIFICANT ANTIBODIES TO RED BLOOD CELL (RBC), WHITE BLOOD CELL (WBC), AND PLATELET ANTIGENS.

Award Information

Agency: Department of Health and Human Services

Branch: N/A

Contract: N/A

Agency Tracking Number: 4877

Amount: $50,000.00

Phase: Phase I

Program: SBIR

Solicitation Topic Code: N/A

Solicitation Number: N/A

Timeline

Solicitation Year: N/A

Award Year: 1986

Award Start Date (Proposal Award Date): N/A

Award End Date (Contract End Date): N/A

Small Business Information

Digital Diagnostics

Po Box 19301 1050 46th Street

Sacramento, CA 95819

United States

DUNS: N/A

HUBZone Owned: No

Woman Owned: No

Socially and Economically Disadvantaged: No

Principal Investigator

Name: DR LINDA R WATKINS
Title: PRINCIPAL INVESTIGATOR
Phone: (916) 456-9531

Business Contact

Phone: () -

Research Institution

N/A

Abstract

THE GOAL OF THIS PHASE I RESEARCH IS TO DEVELOP A NOVEL NONAGGLUTINATION METHOD FOR PRECISE, RAPID, AND COST- EFFECTIVE IDENTIFICATION OF CLINICALLY SIGNIFICANT ANTIBODIES TO RED BLOOD CELL (RBC), WHITE BLOOD CELL (WBC), AND PLATELET ANTIGENS. BY COMBINING AN ENZYME-LINKED ASSAY SYSTEM WITH CELL MEMBRANE FRAGMENTS IMMOBILIZED ON A GLASS MICROFIBER SUBSTRATE, ANTIBODIES IN 0.5 MICROLITER SAMPLES OF HUMAN SERUM CAN BE IDENTIFIED IN ABOUT 10 MINUTES, WITH UP TO 96 TESTS BEING PERFORMED SIMULTANEOUSLY. IN ADDITION,THE IMMOBILIZED ANTIGEN SHOWS NO NOTICEABLE LOSS OF SENSITIVITY FOR AT LEAST 6 MONTHS WHEN STORED AT ROOM TEMPERATURE AND HUMIDITY. THIS STABILITY IS SIGNIFICANTLY GREATER THAN THE THREE WEEK SHELF-LIFE OF REFRIGERATED CELL PANELS ROUTINELY USED. TAKEN TOGETHER, OUR INITIAL WORK STRONGLY SUGGESTS THAT THIS NONAGGLUTINATION METHOD WILL BE A SIGNIFICANT PRACTICAL ADVANCE OVER TECHNIQUES NOW USED FORPRETRANSFUSION TESTING. ONCE REFINED, THIS SYSTEM MAY BE USED TO DETECT OTHER CLINICALLY RELEVANT ANTIBODIES SUCH AS THOSE TO HEPATITIS VIRUS ANTIGENS AND HTLV-III.

* Information listed above is at the time of submission. *

You are here

THE GOAL OF THIS PHASE I RESEARCH IS TO DEVELOP A NOVEL NONAGGLUTINATION METHOD FOR PRECISE, RAPID, AND COST- EFFECTIVE IDENTIFICATION OF CLINICALLY SIGNIFICANT ANTIBODIES TO RED BLOOD CELL (RBC), WHITE BLOOD CELL (WBC), AND PLATELET ANTIGENS.